GlobeNewswire

The Delhi High Court in India has issued an injunction, restraining Sinopharm Weiqida from exporting its “Amoxycillin Trihydrate” product to India, as it infringes the patent of Centrient Pharmaceuticals

Del

The High Court also found Sinopharm Weiqida guilty of Contempt of Court for failing to follow the previously granted preliminary injunction order

ROTTERDAM, the Netherlands, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Centrient Pharmaceuticals (“Centrient”), the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active pharmaceutical ingredient (API) amoxicillin trihydrate. In addition, the Delhi High Court also found Sinopharm Weiqida prima facie guilty of contempt of Court for illegally importing amoxicillin active ingredients in contravention of the previously granted preliminary injunction in place in India since April 2017. The Court further found that Sinopharm Weiqida has infringed the patent of Centrient. 

Centrient, and its wholly owned subsidiaries, Centrient Pharmaceuticals Netherlands B.V. and Centrient Pharmaceuticals India Pvt. Ltd., announced today that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceutical Co., LTD  ("Weiqida") blocking the export, importation and sale of its amoxicillin active ingredient into India. The injunction prevents the importation of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India in any form. 

Weiqida was also found in contempt of the Delhi High Court’s original preliminary injunction order, granted in April 2017, through its continued importation and sale of its amoxicillin trihydrate active pharmaceutical ingredient in India. Centrient will seek monetary compensation for the damage sustained by the illegal shipments, in violation of the preliminary injunction since April 2017.

Centrient wishes to put all buyers of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India on notice (even if such API transits through India under advanced license) to be aware of the above orders of the Delhi High Court. Centrient shall ensure full compliance of the orders of the Delhi High Court and will notify the Indian Customs Authority and other authorities to seize all future Weiqida amoxicillin shipments at the relevant customs facilities.

Karl Rotthier, CEO at Centrient Pharmaceuticals said: “Centrient holds a world-class intellectual property portfolio relating to our innovative, sustainable and environmentally-friendly amoxicillin technology. We will continue to rigorously defend our Intellectual Property assets worldwide as we continue to invest in our innovative R&D programs directed to enzymatically produced, sustainable antimicrobials and statins. We will continue to supply our customers with reliable, non-infringing, top quality amoxicillin.”

About Centrient Pharmaceuticals 

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms. We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. 

With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our 2700 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. 

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (the Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm. 

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

LGC Capital announces that it has increased its ownership to 40.4% of Little Green Pharma in Australia22.5.2019 16:25:00 CESTPressemelding

MONTRÉAL, May 22, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) announces that after much negotiation, it has successfully acquired, from a non-executive founder, additional shares in Australia’s licensed medical cannabis producer Little Green Pharma (LGP) bringing its ownership from 14.1% up to 40.4%. LGP was the first, and is currently the only, domestic cannabis company in Australia producing a locally grown medicinal cannabis medicine for patients. LGC believes the opportunity to increase its ownership in LGP creates significant value for its shareholders and enables the Corporation to further take part in the rapidly expanding Australian medical cannabis market. Little Green Pharma has had over 400 patients approved in Australia, with new patients increasing exponentially month-over-month. The Australian industry represents one of the fastest growing international medical cannabis markets globally, with approximately 6,400 SAS B f

Virtusa recognized as a Visionary in the Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide22.5.2019 16:05:00 CESTPressemelding

SOUTHBOROUGH, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS:VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, today announced that Gartner, Inc. has positioned Virtusa in the Visionaries Quadrant of the 2019 Magic Quadrant for CRM and Customer Experience (CX) Implementation Services, Worldwide. The report evaluated Virtusa along with 17 other companies in CRM and Customer Experience Implementation Services. Virtusa was one of only three companies to be categorized as a Visionary. According to Gartner, “The CX and CRM implementation service market is completing the shift from the implementation of core CRM technology to complex initiatives that not only transform the front office but integrate across the full enterprise’s operations. Customers now demand that organizations provide them with a continuous experience, preserving continuity of user experience across trad

InnovMetric Launches PolyWorks® Metrology Suite 201922.5.2019 15:00:00 CESTPressemelding

Facilitates Deployment of PolyWorks|Inspector™ in Production and Accelerates CNC CMM Measurement Sequences QUEBEC CITY, May 22, 2019 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the launch of the 2019 release of the PolyWorks Metrology Suite. This latest major release delivers new object measurement scripts that open the door to all the custom measurement techniques of clients within the standard PolyWorks workflow, as well as a new assisted sequencing approach that promises to greatly accelerate the time to set up CMM sequences. “Simplifying the lives of our customers while keeping them fully in control. This statement embodies the development philosophy behind the PolyWorks Metrology Suite and the latest 2019 release,” said Marc Soucy, President of InnovMetric. He added, “With its outstanding innovations that combine increased simplicity with important time savings, we are proud to bring the producti

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid22.5.2019 12:55:00 CESTPressemelding

BROOKFIELD, May 22, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM) (TSX: BAM.A) (EURONEXT: BAMA) (“Brookfield”) today announced it has received approval from the Toronto Stock Exchange (“TSX”) for the renewal of its normal course issuer bid to purchase up to 82,530,440 Class A Limited Voting Shares (“Class A Shares”), representing 10% of the public float of Brookfield’s outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange (“NYSE”), and/or alternative trading systems. The period of the normal course issuer bid will extend from May 24, 2019 to May 23, 2020, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted. As at May 17, 2019, the number of Class A Shares issued and outstanding totalled 994,568,660, of which 825,304,404 shares represented the pub

Phenom People Launches University Recruiting, SMS & Internal Mobility Chatbot22.5.2019 10:00:00 CESTPressemelding

Product Innovations to Support Demand for Talent Experience Management LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People, the global leader in Talent Experience Management (TXM), has announced several new features for the Phenom Talent Experience Management platform, adding University Recruiting, SMS, WhatsApp messaging and Internal Mobility chatbot functionality to further support the demands of the new talent economy, which is undergoing major technological and societal shifts. The Phenom Talent Experience Management platform connects the interactions of the four key experiences in the talent lifecycle: candidates, recruiters, employees and management, and delivers a single platform to unify them. Cross-functional insights can be used to power a more personalised and effective experience that meets the demands of today’s talent. The Phenom Talent Experience Management platform furthers chief human resources officers’ top responsibilities across talent acquisition, talent managem

Phenom People Unveils Talent Experience Management Platform Single Platform for Every Talent Experience22.5.2019 10:00:00 CESTPressemelding

LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People has announced Talent Experience Management (TXM) as the holistic approach and SaaS platform to connect every interaction throughout the talent lifecycle by delivering personalised experiences. Talent Experience Management unifies technology and experience design to enhance the talent journey, transforming candidates to employees to brand advocates, while recruiters and management boost productivity and communicate seamlessly. Despite spending massive amounts of money on new investments in HR technology, today’s chief human resources officers still struggle to change the stereotype of their organisation from a cost center to a revenue generator for talent acquisition, talent management and talent evolution. With Talent Experience Management, Phenom People is helping organisations manage the new talent economy, which is undergoing major technological and societal shifts, with a solution that addresses the different needs and experien